Drug General Information (ID: DDIXSJRB3W)
Drug Name			Lopinavir		Drug Info		Boceprevir		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anti-Hiv Agents				Protease Inhibitors
Structure

Mechanism of Lopinavir-Boceprevir Interaction (Severity Level: Major)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Lopinavir				Boceprevir
Mechanism		Reduce the plasma concentration of boceprevir				Boceprevir
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Boceprevir when combined with Lopinavir

Recommended Action
Management		Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, the use of boceprevir in combination with ritonavir-boosted or cobicistat-boosted regimens of atazanavir, darunavir, or lopinavir is not recommended. Moreover, the safety and efficacy of boceprevir has not been established in the HCV/HIV coinfected population.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Evotaz (atazanavir-cobicistat). Bristol-Myers Squibb, Princeton, NJ.
3	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.